Document is current

Article History

Received: 28 August 2021

Accepted: 31 March 2022

First Online: 8 April 2022

Declarations

:

: The study was conducted according to the guidelines of the Declaration of Helsinki. Retrospective analysis of the entire cohort of patients with mCRPC treated with Enzalutamide was approved by the local ethics committee (No. 2007-467-f-S and later amendments, Ethikkommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster).

: <b> Consent for publication</b>

: Not applicable.

: Author RP declares no conflicts of interest.Author KR received consulting and lectureship honoraria from Bayer, ABX, ABR, CRO, Janssen Cilag, AAA and SIRTEX.Author AS has received research grants from German Cancer Aid, speaker honoraria from Janssen and Ipsen, research collaboration with Philips Healthcare and Proteomedix, and owns a patent “Characterization of primary tumors” (039PCT0735).Author AJS received research grants form Astellas and Janssen Cilag and honoraria for advisory-roles from Janssen Cilag, Astellas and Bayer.Author MB has received honoraria for advisory-roles from Janssen Cilag, Astellas, Sanofi and Bayer.

: Author KS has received honoraria for advisory-roles from Amgen, AstraZeneca, Bayer, Janssen Cilag and Ilpsen.